Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | The benefits of PiggyBac transposon-mediated CAR-T cell technology

Shigeki Yagyu, MD, PhD, Kyoto Prefectural University of Medicine, Kyoto, Japan, describes the advantages of PiggyBac transposon-based chimeric antigen receptor (CAR) T-cells. As utilizing viral vectors in T-cell expansion can compromise the efficacy of the CAR T-cells and cause differentiation and T-cell exhaustion, PiggyBac transposons represent a viable alternative to manufacture CAR T-cells. Resting T-cells as a base can prevent exhaustion and using antigen-presenting cells (APCs) instead of CD3 can successfully induce the expansion of T-cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.